• 제목/요약/키워드: Episodic migraine

검색결과 10건 처리시간 0.032초

Are there network differences between the ipsilateral and contralateral hemispheres of pain in patients with episodic migraine without aura?

  • Junseok Jang;Sungyeong Ryu;Dong Ah Lee;Kang Min Park
    • Annals of Clinical Neurophysiology
    • /
    • 제25권2호
    • /
    • pp.93-102
    • /
    • 2023
  • Background: We aimed to identify any differences in the structural covariance network based on structural volume and those in the functional network based on cerebral blood flow between the ipsilateral and contralateral hemispheres of pain in patients with episodic migraine without aura. Methods: We prospectively enrolled 27 patients with migraine without aura, all of whom had unilateral migraine pain. We defined the ipsilateral hemisphere as the side of migraine pain. We measured structural volumes on three-dimensional T1-weighted images and cerebral blood flow using arterial spin labeling magnetic resonance imaging. We then analyzed the structural covariance network based on structural volume and the functional network based on cerebral blood flow using graph theory. Results: There were no significant differences in structural volume or cerebral blood flow between the ipsilateral and contralateral hemispheres. However, there were significant differences between the hemispheres in the structural covariance network and the functional network. In the structural covariance network, the betweenness centrality of the thalamus was lower in the ipsilateral hemisphere than in the contralateral hemisphere. In the functional network, the betweenness centrality of the anterior cingulate and paracingulate gyrus was lower in the ipsilateral hemisphere than in the contralateral hemisphere, while that of the opercular part of the inferior frontal gyrus was higher in the former hemisphere. Conclusions: The present findings indicate that there are significant differences in the structural covariance network and the functional network between the ipsilateral and contralateral hemispheres of pain in patients with episodic migraine without aura.

편두통 예방을 위한 erenumab의 유효성 및 안전성에 관한 체계적 고찰 (Systematic Review on the Efficacy and Safety of Erenumab for the Prevention of Migraine)

  • 손병우;채현우;지은희;유봉규
    • 한국임상약학회지
    • /
    • 제29권2호
    • /
    • pp.71-78
    • /
    • 2019
  • Objective: This study aimed to provide efficacy and safety information on the use of erenumab for prevention of episodic and chronic migraines. Methods: The keywords "Erenumab and migraine" were used to search the PubMed database to then compile efficacy and safety data for erenumab. Data from relevant Phase 2 and Phase 3 clinical trials were analyzed, using RevMan for statistical analysis. Results: Three clinical trials (one Phase 2 and two Phase 3 studies) were retrieved. All three trials used the same primary endpoint (change from baseline in monthly migraine days (CBMD)) to evaluate efficacy and safety of erenumab use for prevention of episodic and chronic migraines. Subcutaneous doses of erenumab (70 or 140 mg) were administered monthly in each trial, for 3 months (Studies 2, and 3) or 6 months (Study 1). The mean differences in CBMD in the 70 mg and 140 mg erenumab arms were -1.36 and -1.98, respectively, compared to that in the placebo arm. Some adverse events, such as nasopharyngitis and upper respiratory tract infection, were reported, but no differences in safety between erenumab and placebo were found to be significant. Conclusions: Erenumab showed superior efficacy in prevention of migraines compared to placebo. However, additional information regarding the long-term safety of erenumab should be collected. Therefore, post-marketing surveillance for adverse events is needed.

반복 발작성 긴장성 두통을 호소하는 소양인(少陽人) 태음인(太陰人) 치험 2례 (Two Cases of Repetitive Episodic Tension-type Headache Patients who were Constitutionally Typed as Soyangin and Taeeumin)

  • 박병주;신현상;강미정;이지원;장현수;이준희;이의주;고병희
    • 사상체질의학회지
    • /
    • 제22권2호
    • /
    • pp.123-134
    • /
    • 2010
  • 1. Objectives: This study reports two cases of repetitive episodic tension-type headache patients who were each constitutionally typed as the Taeeum type and the Soyang type and respectively treated with Yanggyeoksanhwa-tang and Galgeunhaegi-tang. 2. Methods: The patients' subjective and objective symptoms were observed daily, and the VAS scores for the main symptoms were recorded daily throughout hospitalization period. When deemed necessary, other assessment tools were engaged (Migraine-Specific Quality of Life questionnaire, Migraine Disablity Assessment questionnaire, Headache Impact Test-6, etc.). 3. Results: The Soyang Type patient's headache improved by the end of hospitalization, with a dramatic drop in the VAS score from VAS 10 to VAS 2. The Taeeum Type patient's headache also showed improvement, with an equally dramatic decrease in the VAS score from VAS 10 to VAS 2. 4. Conclusion: Although the two patients were experiencing the same symptoms of repetitive episodic tension-type headache, they were each given different medicinal interventions in accordance to their respective constitutional types. This series of cases is notable in that the two widely different medications (Yanggyeoksanhwa-tang and Galgeunhaegi-tang) were applied to specifically conforming pathologies (the Sogal symptomatology and the Ganyeol symptomatology, respectively) to produce equally dramatic improvements.

The Effects of Coenzyme Q10 Supplementation on Oxidative Status and Lipid Profile in Migraine Patients: A Randomized Double-Blinded Controlled Clinical Trial

  • Monireh Dahri;Atefeh Sarafan Sadeghi;Naseh Pahlavani;Elyas Nattagh-Eshtivani;Mazyar Hashemilar;Mohammad Asghari-Jafarabadi;Hanieh Barghchi;Ali Tarighat-Esfanjani
    • Clinical Nutrition Research
    • /
    • 제12권4호
    • /
    • pp.257-268
    • /
    • 2023
  • Migraine is a common neurological disease correlated with oxidative stress and lipid profile disorders. The present study was designed to determine the effects of Coenzyme Q10 (Co-Q10) supplementation on oxidative status and lipid profile in migraine individuals. This clinical trial was conducted on 84 females aged 18-50 years, diagnosed for episodic migraine according to the International Headache Society. Subjects were randomized to receive either Co-Q10 supplement (400 mg/day) or placebo for 12 weeks. Lipid profile and oxidative stress indices including malondialdehyde (MDA) and total antioxidant capacity (TAC) were measured before and after intervention in both groups. Also, anthropometric indices, dietary intakes, and clinical features were collected. Data analysis was conducted using SPSS version 16. Seventy-seven of the participants, with mean age of 33.70 ± 7.75 years, completed the study. After 12-week intervention, Co-Q10 led to a significant decrease in MDA levels compared to placebo (p = 0.009), with no effect on TAC levels (p = 0.106). A significant increase in serum Co-Q10 concentration and high-density lipoprotein cholesterol (HDL-C) level in Co-Q10 group was observed, but no significant differences were found in other lipid profile variables (low-density lipoprotein cholesterol, triglycerides and total cholesterol). Among anthropometric variables, Co-Q10 only caused a significant reduction in body fat percentage (BFP), but we did not find any significant changes in others. A 12-week Co-Q10 supplementation led to significant improvement in clinical features, BFP, and HDL-C level among migraine individuals.

주기성 구토증(cyclic vomiting syndrome)의 장기 추적 관찰 -이형 편두통(migraine variant)으로의 이행 과정인가?- (Long Term Follow-Up of Cyclic Vomiting Syndrome)

  • 황진복;오희종;최광해
    • Pediatric Gastroenterology, Hepatology & Nutrition
    • /
    • 제3권1호
    • /
    • pp.75-83
    • /
    • 2000
  • 저자들은 주기성 구토증으로 진단된 3명의 소아에서 6년 이상의 장기 추적관찰을 통하여 임상양상의 다양한 변화과정을 관찰하여 보고, 뇌파검사의 이상소견을 근거로 이형 편두통의 형태로 진행하여 가는 과정을 관찰하였다. 시간의 경과에 따라 구토 발병 주기, 기간의 변화와 함께 위배출능 저하, 두통의 발현, 뇌파의 이상 등 다양한 임상 양상의 변화를 보여주며, 2례에서는 증상의 소실이 관찰되었다. 특히, 뇌파 검사상 증상 발현시 발생하는 서파는 편두통의 발생 직전에 뇌혈류의 감소로 발생하는 양상과 매우 유사하며, 주기성 구토증과 편두통의 관련성을 시사하여 주는 소견으로, 진단 및 치료적 접근시 반드시 고려하여야 한다. 주기성 구통증은 이형 편두통으로의 이행 과정인가?

  • PDF

Topiramate 투여로 호전된 주기성 구토증 1례 (Topiramate can reduce the number of episodic attacks in cyclic vomiting syndrome : a case report)

  • 염미선;배근욱;유수영;고태성
    • Clinical and Experimental Pediatrics
    • /
    • 제50권4호
    • /
    • pp.386-389
    • /
    • 2007
  • 주기성 구토증(cyclic vomiting syndrome, CVS)은 예측 불가능한 심한 구토가 특별한 원인 없이 시작되어 각 개인마다 일정한 임상 양상을 보이며 수 시간에서 수일간 지속되다가 저절로 호전되는 것을 반복하는 질환으로서, 그 임상 양상은 편두통과 많은 공통점을 보이며 그 병리생리학적 원인이 편두통과 유사한 것으로 추정되어지고 있다. 저자들은 만 3세 경부터 시작된 발작적이고 반복적인 주기적 구토를 주소로 내원한 5세 남아에서 주기적 구토증을 진단하였으며, 이 환아에서 대규모의 임상 연구를 통해 단독 요법으로 편두통의 예방에 효능이 있음이 인정된 광범위 항경련제인 topiramate(TPM)를 투여하여 그 증상이 호전됨을 경험하고 이를 보고하는 바이다.

Channelopathies

  • Kim, June-Bum
    • Clinical and Experimental Pediatrics
    • /
    • 제57권1호
    • /
    • pp.1-18
    • /
    • 2014
  • Channelopathies are a heterogeneous group of disorders resulting from the dysfunction of ion channels located in the membranes of all cells and many cellular organelles. These include diseases of the nervous system (e.g., generalized epilepsy with febrile seizures plus, familial hemiplegic migraine, episodic ataxia, and hyperkalemic and hypokalemic periodic paralysis), the cardiovascular system (e.g., long QT syndrome, short QT syndrome, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia), the respiratory system (e.g., cystic fibrosis), the endocrine system (e.g., neonatal diabetes mellitus, familial hyperinsulinemic hypoglycemia, thyrotoxic hypokalemic periodic paralysis, and familial hyperaldosteronism), the urinary system (e.g., Bartter syndrome, nephrogenic diabetes insipidus, autosomal-dominant polycystic kidney disease, and hypomagnesemia with secondary hypocalcemia), and the immune system (e.g., myasthenia gravis, neuromyelitis optica, Isaac syndrome, and anti-NMDA [N-methyl-D-aspartate] receptor encephalitis). The field of channelopathies is expanding rapidly, as is the utility of molecular-genetic and electrophysiological studies. This review provides a brief overview and update of channelopathies, with a focus on recent advances in the pathophysiological mechanisms that may help clinicians better understand, diagnose, and develop treatments for these diseases.

두통의 치료 (Treatment of the Headache)

  • 정경천
    • 정신신체의학
    • /
    • 제7권2호
    • /
    • pp.263-273
    • /
    • 1999
  • 두통은 인류의 가장 흔한 호소 중의 하나로 임상에서 흔히 보는 장애이다. 두통은 뇌막염, 뇌출혈, 또는 뇌종양과 같은 다른 질환의 증상일수 있으나, 또한 편두통이나 군발두통 등과 같은 질병 자체로 표현된다. 일차적으로 두통 장애의 역학이나 국제 두통학회의 진단기준을 이해하고 흔치 않으나 심각한 이차적인 두통장애와 감별에 관심을 둬야 한다. 환자가 일차 두통장애의 기준에 맞으면 신경학적 진단검사의 보충이 없어도 치료를 시작한다. 두통 유형, 표현 양상, 동통기간과 강도 등에 따라 진통소염제나 혼합진통제, 혈관작용의 항편두통 약물 또는 신경이완제나 corticosteroid등을 선택한다. 편두통의 빈도와 강도에 따라 예방치료가 보통 4~6개월간 조절한다. 긴장형 두통은 발작성과 만성두통으로 구분되나 치료적으로는 급성완화와 예방치료로 시도된다. 많은 만성매일두통 환자들이 진통제나 ergotamine을 과용하고 있으며 그들의 의존성과 내재된 갈등조절, 수면장애, 우울등으로 과용된 약물의 제한이 쉽지 않다. 치료의 첫단계는 약물을 끊고 조심스럽게 대치요법을 시행한다.

  • PDF

두통의 특성에 관한 연구 (A Study on Prevalence and Characteristics of Headache)

  • Hyun-Koo Kim;Bo-Young Um;Sung-Chang Chung
    • Journal of Oral Medicine and Pain
    • /
    • 제18권2호
    • /
    • pp.55-69
    • /
    • 1993
  • The purpose of this study is investigation on prevalence and clinical characteristics of headache among 10-39 years men and women. Information could be obtained with the questionnaire, and 1952 respondents completed the questionnaire. All participants were asked if they had experienced headache. Those responding positively were further questioned regarding the frequency, severity, character, location and duration of headache and were questioned regarding the experience of medical cunsultation and taking analgesics. The obtained results were as follows : 1. The life time prevalence of headache was 49.6% among men, 70.8% among women and 61.5% in all. 2. The prevalence of episodic tension type headache, chronic tension type headache, migraine, mixed type headache in this population was 27.1%, 5.0%, 2.8%, 23.1% respectively. 3. Headache duration was classified as less than 1 hour, 1-6 hours, 6012 hours, more than 12 hours for 1 day. The percentage of each other case is 41.8%, 46.2%, 7.4% and 4.4% of headache suffers respectively. 4. As regards the severity of headache, 4.2% of headache suffers had a very mild pain intensity, 17.9% a mild pain, 57.7% a moderate pain, 18.1% a severe pain and 2.2% a quite severe pain. 5. Headache occured at morning in 8.2% of headache suffers, at afternoon in 9.4%, at evening in 18.1%, at night in 4.3% and at anytime in 59.9%. 6. 11.7% of headache suffers among men consulted doctor, 13.9% among women and 13.1% in all. 7. 66.2% of headache suffers didnt have any analgesics because of their pain, 33.8% of headache suffers had analgesics because of their pain.

  • PDF

거짓침을 이용한 침연구의 현황 (Current evidence on acupuncture from sham needle studies)

  • 이향숙
    • Korean Journal of Acupuncture
    • /
    • 제23권1호
    • /
    • pp.95-109
    • /
    • 2006
  • Objectives : There has been a considerable debate about how to best control for placebo effects in clinical trials of acupuncture. Recently several sham needles were developed and validated. This study aimed at summarising the validation studies of these needles and evaluating the outcomes of the randomised controlled trials (RCTs) using them. Methods : Computerised literature searches were performed using 'acupuncture' AND 'placebo OR sham' with a limitation of the results to RCTs in Medline via PubMed and the Cochrane Library. Only formally validated sham needle controlled studies were included. Data were extracted regarding study design, condition, sample size, credibility testing, intervention and outcomes. Methodological quality was assessed using a modified Jadad scale. Results : Three validated sham needles by Streitberger, Park, and Fink, were identified. Acupuncture's effectiveness for various conditions was tested using these needles in 12 RCTs. Real acupuncture was superior to sham acupuncture for rotator cuff tendonitis and hypertension. No significant differences between real acupuncture and sham acupuncture emerged for chemotherapy-related nausea and vomiting, postoperative nausea and vomiting, menstrually related migraine, acute stroke rehabilitation, chronic/episodic tension-type headache, neutrophil respiratory burst in healthy volunteers, alcohol withdrawal symptoms and chronic poststroke leg spasticity. Conclusions : The new sham devices have been adequately validated and may be useful tools for investigating specific research question. In spite of the sham needle's limits, the results of RCTs using such devices tend to suggest that the clinical effects of acupuncture are largely due to a placebo response.

  • PDF